One Technology Place
About EMD Serono
At the EMD Group, around 40,000 people in more than 60 countries develop pharmaceutical and chemical innovations. In 2010 the company generated total revenues of EUR 9.3 billion. It is the world’s oldest pharmaceutical and chemical company with roots dating back to 1668. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.
From the start of industrial production in 1827, to initial research on liquid crystals more than 100 years ago, up to our entry into targeted cancer therapy with the launch of Erbitux®, many milestones in our history provide strong evidence of the pioneering spirit of the people at EMD. From innovative drugs to treat multiple sclerosis, cold remedies to new technologies for energy-efficient light sources our pioneering spirit in research and our experience enable us to develop products that improve quality of life.
Since going public in 1995, the company’s operating activities are under the umbrella of Merck KGaA Darmstadt, Germany.
Do you want to continue to experiment, analyze and break new ground? Welcome to EMD. When it comes to innovations, you will find us in the front ranks. And the breadth of our ceative research is far-reaching: from medicines, through opportunities in bio-research and bio-production, all the way to liquid crystals for LCDs. Enough latitude, in other words, to make your passion a true calling. Bring us entrepreneurial flair, plenty of team spirit and a total commitment to delivering the best possible results for our customers, and you’ll go far. You’ll enjoy all the interest and exposure of working in multidisciplinary, international teams. Depending on your field of expertise, you may even have the chance to develop across business sectors and functions.
To find out where you could go in an organization that’s part of Merck KGaA, Darmstadt, Germany, a global force in chemicals and pharmaceuticals with operations in more than countries and revenues of €9.3 billion in 2010, please visit come2emd.com.
EMD Group is an Equal Opportunity Employer.
EMD Serono is the largest division of the EMD Group and discovers, develops, manufactures and commercializes innovative prescription drugs and therapies for high unmet medical needs. The focus lies in specialist therapeutic areas such as oncology, multiple sclerosis and infertility. Through their targeted effect, these medicines help patients to live a longer and better life. Many consumers around the world trust a wide range of well-known brands that EMD develops, manufactures and markets for the OTC (over-thecounter) pharmaceutical sector.
Our broad range of specialty chemicals are used in technologically sophisticated applications ranging from liquid crystal, to effect pigments and cosmetic ingredients. The EMD Group is the global leader in the liquid crystals market. Liquid crystals are used throughout the world, in LCD TVs, monitors, tablet computers, notebooks, mobile phones, and digital cameras. In addition to the display materials business, the Performance Materials division focuses on materials for energy-saving lighting using LEDs (light-emitting diodes) and OLEDs (organic LEDs). Pigments for the plastics, printing and coatings industries as well as for cosmetic applications are an important part of the Performance Materials portfolio. Moreover, the division is the market leader for pearl-luster effect pigments.
With the EMD Millipore division, the EMD Group is a leading life science company, which offers products, applications and solutions for protein research and cell biology as well as for the manufacture of chemical-based and biopharmaceutical drugs. The portfolio comprises products for life science research such as assays, biomarkers and targeted solutions, as well as bioprocessing, lab water purification and filtration. Additionally, the division supplies specialty chemicals mainly to regulated markets, for example the pharmaceutical, cosmetics and food industries. Analytical and scientific laboratories use the reagents and test kits supplied by the division. The EMD Millipore portfolio comprises more than 40,000 products and processes.
Thank you in advance! I am looking forward to hearing from you.
83 articles with EMD Serono
FDA Accepts File for Cladribine Tablets as Potential Treatment for Relapsing Forms of Multiple Sclerosis
The New Drug Application includes close to 12,000 patient years of data and up to 10 years of safety data in some patients
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operating as EMD Serono in North America, today announced the presentation of new efficacy and benefit-risk assessment data for MAVENCLAD™ (Cladribine Tablets) at the 4th Congress of the European Association of Neurology (EAN)
Precision medicine company names Chief Medical Officer, Chief Business Officer and Chief Technology Officer.
EMD Serono announced that six abstracts including two poster presentations on Cladribine Tablets.
14th Annual EMD Serono Specialty Digest™ Educates Health Plans on Latest Trends in Unmet Payer Needs and Patient-Centric Services
EMD Serono announced the launch of the 14th edition of the EMD Serono Specialty Digest™ at the Asembia Specialty Pharmacy Summit in Las Vegas, NV.
Earlier this month Roche acquired a regenerative therapy program for MS from Inception Sciences and now today Roche’s Genentech announced new data showcasing the efficacy of Ocrevus in relapsing multiple sclerosis (RMS).
EMD Serono R&D Building Earns First WELL Gold Certification™ in U.S. for New & Existing Building Project
Prestigious building distinction reflects company's commitment to employee health and wellness
Three-year collaboration to focus on working mothers as a part of EMD Serono's support of the Healthy Women, Healthy Economies initiative
The six posters evaluate the safety of Cladribine Tablets and its impact on the immune system via post hoc analyses of the CLARITY, CLARITY Extension, and ORACLE-MS trials, as well as the PREMIERE registry study.
In this role, Dr. Walsh will direct and manage the N&I Medical Affairs team to develop and implement plans for Rebif and our products in development, both in the US and in collaboration with Global Medical Affairs.
In this role, Dr. Su will collaborate with the local and global medical, development and regulatory teams to drive the progress of EMD Serono's portfolio and pipeline, as well as enhance scientific leadership in the US.
Originally approved in 2013, the new pen injector was reported to be easy to learn and easy to use in a simulated-use study including 86 women with infertility and 30 fertility nurses.
EMD Serono today announced the appointment of Robert Truckenmiller as Senior VP, Market Access & Customer Solutions.
EMD Serono Release: Investigational Cladribine Tablets Demonstrates Sustained Disease Control Over 4 Years With Maximum Of 20 Days Oral Treatment
EMD Serono Release: Investigational Cladribine Tablets Data Show Greater Treatment Effect In Relapsing MS Patients At A Higher Risk Of Disease Progression
EMD Serono Release: FDA Grants Approval For BAVENCIO (Avelumab), The First Immunotherapy Approved For Metastatic Merkel Cell Carcinoma
EMD Serono Release: Richard R. Smith Joins Company As Senior Vice President And Head Of US Fertility And Endocrinology
EMD Serono Release: FDA Accepts The Biologics License Application For Avelumab For The Treatment Of Metastatic Merkel Cell Carcinoma For Priority Review